Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
22/08/2007 12:44
PR Newswire
AMSTERDAM, August 22 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today announced that it will release its
financial results for the first six months of 2007 on Wednesday, August 29,
2007 at 8 am Central European Time (CET).
To discuss these results, the Company will conduct a
conference call at 10 am CET. Netherlands Dial In: +31(0)800-949-4517 (toll
free); US Dial In: +1-866-291-4166 (toll free); UK Dial In: +44-207-107-0611.
To listen to the conference call live via the internet, visit
the investor relations portion of the AMT website at http://www.amtbv.com.
Please go to the website 15 minutes prior to the call to register, download
and install the necessary audio software.
About Amsterdam Molecular Therapeutics
AMT has a unique gene therapy platform that to date appears to
circumvent many if not all of the obstacles that have prevented gene therapy
to become a mainstay of clinical medicine. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV production platform. As such, AMT's proprietary platform holds
tremendous promise for thousands of rare (orphan) diseases that are caused by
one faulty gene. AMT currently has a product pipeline with six products at
different stages of development.
PRN NLD
For information: André Verwei, CFO, +31-20-566-5686, a.verwei@amtbv.com; Hans Herklots, +31-20-566-8125, h.herklots@amtbv.com